Abstract-Certain forms of coronary artery disease do not respond to treatment with Ca 2ϩ channel blockers, and a role for endothelin-1 (ET-1) in Ca 2ϩ antagonist-insensitive forms of coronary vasospasm has been suggested; however, the signaling mechanisms involved are unclear. We tested the hypothesis that a component of ET-1-induced coronary smooth muscle contraction is Ca 2ϩ antagonist-insensitive and involves activation of protein kinase C (PKC). Cell contraction was measured in smooth muscle cells isolated from porcine coronary artery, [Ca 2ϩ ] i was measured in fura-2 loaded cells, and the cytosolic and particulate fractions were examined for PKC activity and reactivity with isoform-specific PKC antibodies using Western blot analysis. In Hank' 
C oronary vasospasm is often associated with ischemic heart disease leading to different forms of angina and myocardial infarction, and excessive coronary vasoconstriction in response to endogenous vasoconstrictors has been suggested as one potential cause. 1, 2 Several potent endogenous vasoconstrictors have been described, including endothelin-1 (ET-1). 3, 4 Plasma levels of ET-1 are increased in patients with coronary artery disease. [5] [6] [7] [8] [9] [10] [11] Also, coronary artery perfusion with ET-1 in dogs is associated with severe coronary vasoconstriction and vasospasm, 12, 13 suggesting a role of ET-1 in coronary vasospasm and coronary artery disease.
Ca 2ϩ channel blockers such as verapamil and diltiazem are often recommended to decrease coronary vasospasm and reduce the incidence of angina and myocardial infarction. 14 -17 However, certain forms of angina and coronary artery disease do not respond adequately to treatment with Ca 2ϩ channel blockers. 18, 19 The causes of Ca 2ϩ antagonist-insensitive forms of coronary vasospasm are unclear, but could be due to decreased sensitivity of the coronary smooth muscle contraction induced by certain endogenous vasoconstrictors to Ca 2ϩ channel blockers. For example, although ET-1 is a potent coronary vasoconstrictor, 3, 4, 12, 13 the sensitivity of the ET-1-stimulated mechanisms of coronary smooth muscle contraction to Ca 2ϩ channel blockers is unclear. A potential cause of Ca 2ϩ antagonist-insensitive forms of coronary vasospasm is possible activation of a Ca 2ϩ -sensitization, or perhaps Ca 2ϩ -independent, mechanism of smooth muscle contraction. Vascular smooth muscle contraction is triggered by increases in intracellular free Ca 2ϩ ([Ca 2ϩ ] i ) due to Ca 2ϩ release from the intracellular stores and Ca 2ϩ entry from the extracellular space. 20 -22 ET-1 has been shown to increase [Ca 2ϩ ] i and to stimulate the Ca 2ϩ mobilization mechanisms of vascular smooth muscle contraction. 23, 24 In addition to the increase in [Ca 2ϩ ] i , the interaction of a vasoconstrictor agonist with its receptor is coupled to increased breakdown of plasma membrane phospholipids and increased production of diacylglycerol (DAG). 25, 26 DAG binds to and activates protein kinase C (PKC). PKC is a family of several Ca 2ϩ -dependent and Ca 2ϩ -independent isoforms that have different enzyme properties, subcellular distributions, substrates, and functions. 27, 28 PKC is mainly cytosolic under resting conditions and undergoes translocation to the particulate fraction when it is activated by endogenous DAG or exogenous phorbol esters. 25, 26 Also, direct activation of PKC by phorbol esters causes sustained contraction of vascular smooth muscle, suggesting a role for PKC in regulating smooth muscle contraction. 29, 30 However, the role of PKC as a potential signaling mechanism of the Ca 2ϩ antagonist-insensitive forms of coronary contraction, in general, and the ET-1 induced coronary smooth muscle, in particular, has not been fully investigated.
The purpose of this study was to test the hypothesis that a component of ET-1-induced coronary smooth muscle contraction is Ca 2ϩ antagonist-insensitive and involves activation of specific PKC isoforms. Since the PKC family includes both Ca 2ϩ -dependent and Ca 2ϩ -independent isoforms, any ET-1-induced changes in [Ca 2ϩ ] i may determine which PKC isoform is activated. Therefore, experiments were designed to investigate the effects of ET-1 on coronary smooth muscle cell contraction, [Ca 2ϩ ] i , and PKC activity. The effects of ET-1 were compared with those of phorbol 12-myristate 13-acetate (PMA), a direct activator of PKC, and with membrane depolarization by high KCl solution, activator of Ca 2ϩ entry from the extracellular space. The sensitivity of coronary smooth muscle cell contraction, [Ca 2ϩ ] i and PKC activity to two Ca 2ϩ channel antagonists, namely verapamil and diltiazem, and mechanistically distinct PKC inhibitors, namely calphostin C and selective ⑀-PKC V1-2 inhibitory peptide, [31] [32] [33] [34] was also investigated.
Methods

Tissue Preparation
Castrated male Yorkshire pigs (30 kg) were anesthetized by inhalation of isoflurane. The heart was excised, and the left anterior descending coronary artery was dissected and sectioned into 2ϫ2 mm strips. All procedures followed the guidelines of the Institutional Animal Care and Use Committee.
Cell Isolation
Coronary strips (50 mg) were placed in a digestion mixture containing collagenase (236 U/mg, Worthington), elastase (3.25 U/mg, Boehringer Mannheim), and trypsin inhibitor (10 000 U/mL, Sigma) in 7.5 mL Ca 2ϩ -and Mg 2ϩ -free Hank's solution. [35] [36] [37] The tissue preparation was placed in shaking water bath at 34°C in an atmosphere of 95% O 2 -5% CO 2 . Isolated cells were poured over glass coverslips, and Ca 2ϩ was gradually added back to avoid the "calcium paradox." 38 
Contraction Studies
Cells were placed on the stage of an inverted Nikon microscope and viewed using 100ϫ objective. Only viable, healthy, and spindleshaped cells Ն60 m in length were selected. Viable cells adhered to glass coverslips and appeared bright and without visible nucleus. Cell viability was confirmed by their contraction in response to ET-1 and high KCl. Cell images were acquired using a PXL CCD camera and changes in cell length were measured after stimulation with ET-1, KCl, or the phorbol ester PMA. Cell contraction was expressed as the final cell length (L) as a fraction of the initial cell length (L i ). Contraction measurements were made at 37°C. 40 All experiments were performed at 37°C.
Measurement of [
Tissue Fractions
Tissue strips (Ϸ80 mg) were transferred to homogenization buffer as previously described. 41, 42 The tissue was homogenized using a 2 mL tight-fitting homogenizer at 4°C, centrifuged at 100 000 rpm for 20 minutes, and the supernatant was used as the cytosolic fraction. The pellet was re-suspended in homogenization buffer and centrifuged at 100 000 rpm for 20 minutes. The supernatant was used as the particulate fraction. Protein concentrations in tissue fractions were determined using a protein assay kit (Bio-Rad).
PKC Activity
PKC activity was determined in cytosolic and particulate fractions by measuring the incorporation of 32 P from [␥ 32 P]ATP (ICN) into histone or myelin basic protein (MBP). 41, 42 The assay mixture contained 25 mmol/L Tris.HCl (pH 7.5), 10 mmol/L MgCl 2 , 200 g/mL histone IIIS or MBP, 80 g/mL phosphatidylserine, 30 g/mL diolein, [␥ 32 P]ATP (2ϫ10 5 cpm/nmol), and 0.5 to 3 g protein. After 5 minutes incubation at 30°C, the reaction was stopped by spotting 25 L of the assay mixture onto phosphocellulose discs. The discs were washed with 5% trichloroacetic acid, placed in 4 mL Ecolite scintillation cocktail, and the radioactivity was measured in liquid scintillation counter.
Immunoblotting
Protein-matched samples of cytosolic and particulate fractions were subjected to electrophoresis on 8% SDS polyacrylamide gels then transferred electrophoretically to nitrocellulose membranes. The membranes were incubated in 5% dried nonfat milk in PBS-Tween at 22°C for 1 hour then labeled with anti-PKC antibody at 4°C overnight. Polyclonal antibodies to ␣-, ␤-, ␥-, ␦-, ⑀-and -PKC (Gibco) were used. [41] [42] [43] [44] To maintain constant labeling conditions, we used the same antibody titer (1:500) and protein concentration (10 g) in all tissue samples. The nitrocellulose membranes were washed in PBS, then incubated in horseradish peroxidase-conjugated anti-rabbit IgG for 1.5 hours. The blots were washed with PBS and visualized with enhanced chemiluminescence detection system (Amersham). The reactive bands were analyzed using GS-700 imaging densitometer (Bio-Rad).
Drugs and Chemicals
ET-1 (Sigma), verapamil, and diltiazem (Calbiochem) were dissolved in distilled water. Neomycin and U-73122 were purchased from Biomol. PMA (Alexis), calphostin C (Kamiya), and myristoyl-tagged ⑀-PKC V1-2 inhibitory peptide (Biomol) were dissolved in dimethylsulfoxide (DMSO). Final DMSO concentration in solution was Յ0.1%.
Statistical Analysis
Data from several cells of the same pig were averaged, and the data presented for each individual pig. The data from different pigs were analyzed and expressed as meanϮSEM with "n" value representing the number of pigs. Data were compared using Student t test for unpaired data with PϽ0.05 considered significant. Figure  4B, 4C) . Also, ⑀-PKC V1-2 inhibitory peptide (10 Ϫ4 mol/L) decreased the verapamil-insensitive ET-1-induced PKC activity ratio to 0.6Ϯ0.1, a level that was not significantly different from basal PKC activity ratio.
Results
In cells incubated in
In comparison with ET-1, the phorbol ester PMA (10 Ϫ6 mol/L) caused significant increases in PKC activity that were inhibited by calphostin, but not by verapamil ( Figure 4C ). In tissues stimulated with KCl (51 mmol/L), no increases in PKC activity could be observed, and pretreating the tissues with verapamil, diltiazem, or calphostin did not change PKC activity ( Figure 4C ). Western blot analysis revealed significant amounts of ␣, ␦, ⑀, and -PKC. In resting tissues, ␣-and ⑀-PKC were mainly cytosolic ( Figure 5 ), ␦-PKC was slightly more in the particulate fraction, while -PKC was equally distributed in the cytosolic and particulate fraction as previously described. 15, 17 ET-1 caused significant increase in the distribution of Ca 2ϩ -dependent ␣-PKC ( Figure 5A ) and Ca 2ϩ -independent ⑀-PKC ( Figure 5B ) in the particulate fraction compared with the cytosolic fraction. Pretreatment with verapamil inhibited ET-1-induced changes in the distribution of ␣-PKC ( Figure  5A ), but not ⑀-PKC ( Figure 5B ). Calphostin inhibited ET-1-induced changes in the distribution of both ␣-PKC ( Figure  5A ) and ⑀-PKC ( Figure 5B ). PMA did not change the distribution of ␣-PKC, but caused an increase in the distribution of ⑀-PKC in the particulate fraction that was inhibited in tissues pretreated with calphostin.
Experiments in Ca 2ϩ -free (2mmol/L EGTA) solution indicated that significant ET-1-induced cell contraction, PKC activity, and increases in ⑀-PKC distribution in the particulate fraction could still be observed in the absence of extracellular Ca 2ϩ entry ( Figure 6 ). The ET-1-induced cell contraction, PKC activity, and increased ⑀-PKC distribution in the particulate fraction in Ca 2ϩ -free solution were inhibited in tissues pretreated with the selective ⑀-PKC V1-2 inhibitory peptide ( Figure 6 ).
Discussion
The main findings of the present study are: (1) The interaction of an agonist with its receptor activates phospholipase C and increases the hydrolysis of phosphatidlylinositol-4,5-bisphosphate into inositol-1,4,5-trisphosphate and diacylglycerol. 25, 26, 41 Inositol-1,4,5-trisphosphate stimulates Ca 2ϩ release from intracellular stores and diacylglycerol stimulates PKC. 25, 26 The inhibition of ET-1-induced cell contraction by the phospholipase C inhibitors neomycin and U-73122 provides evidence that ET-1 responses involve activation of phospholipase C and hydrolysis of plasma membrane phospholipids.
ET-1 (10 Ϫ7 mol/L)-induced coronary smooth muscle contraction in Ca 2ϩ -containing solution was associated with an initial followed by maintained elevation in [ from intracellular stores in response to the hydrolysis products of plasma membrane phospholipids. Also, the observation that a small transient ET- (3) PMA-induced contraction and PKC activity were inhibited by calphostin, but not by verapamil. The observation that calphostin, at concentrations that completely inhibit PMA-induced contraction and PKC activity, caused significant inhibition of ET-1 contraction suggests that a significant component of ET-1 contraction involves activation of PKC. Also, combined pretreatment of the cells with calphostin and verapamil, both of which are partial inhibitors of ET-1 contraction, completely inhibited ET-1 contraction. These data suggest that calphostin inhibits the Ca 2ϩ antagonist-insensitive component of ET-1 contraction, and therefore, provide evidence that the Ca 2ϩ antagonist-insensitive component of ET-1 contraction involves activation of PKC. This is supported by the observation that ET-1 caused an increase in PKC activity that was inhibited by calphostin.
PKC is a family of Ca 2ϩ -dependent and Ca 2ϩ -independent isoforms. 25, 26 The immunoblotting data suggest that in Ca 2ϩ -containing solution ET-1 causes increases in the amount of Ca 2ϩ -dependent ␣-PKC and Ca 2ϩ -independent ⑀-PKC in the particulate fraction compared with the cytosolic fraction, possibly due to PKC translocation from the cytosolic to particulate fraction. PKC translocation to the surface membrane allows the binding of cofactors such as membrane phospholipid and diacylglycerol to the PKC regulatory domain. [25] [26] [27] [28] That will lead to full activation of PKC, conformational change and unlocking of the ATP and substrate binding site in the PKC catalytic domain. 25, 26 These conformational changes would in turn allow PKC to phosphorylate the appropriate substrate and initiate a PKC-dependent response (eg, smooth muscle contraction). [25] [26] [27] [28] [29] [30] Thus, the immunoblotting data suggest that in Ca 2ϩ -containing solution, ET-1 causes activation and translocation of Ca 2ϩ -dependent ␣-PKC and Ca 2ϩ -independent ⑀-PKC. The ET-1-induced translocation of ␣-and ⑀-PKC is inhibited by calphostin, confirming the specificity of the PKC translocation assay. Verapamil inhibited ET-1-induced translocation of ␣-PKC, but not that of ⑀-PKC. The inhibition of ␣-PKC translocation by verapamil is consistent with reports that ␣-PKC is Ca 2ϩ -dependent. 25, 26 The lack of inhibition of ⑀-PKC by verapamil is in accordance with reports that ⑀-PKC is Ca 2ϩ -independent 20 39, 41 We should also note that calphostin inhibited ET-1-induced translocation of ␣-and ⑀-PKC and PMAinduced activation and translocation of ⑀-PKC. Calphostin competes with PMA or diacyglycerol for binding to the regulatory domain, 33, 34 and therefore inhibited the translocation of both ␣-and ⑀-PKC and abolished Ca 2ϩ -sensitive and Ca 2ϩ -insensitive PKC activity. On the other hand, ⑀-PKC V1-2 , a 14 to 21 peptide sequence derived from the first variable region V1 of the regulatory domain of ⑀-PKC, 31, 32 and therefore specifically prevented ⑀-PKC translocation and inhibited Ca 2ϩ -insensitive PKC activity.
Perspectives
A significant component of ET-1-induced coronary smooth muscle contraction requires both Ca 2ϩ entry and PKC activation and is inhibited by both Ca 2ϩ channel blockers and PKC inhibitors; thus, it appears to involve Ca 2ϩ -dependent ␣-PKC isoform. An additional component of ET-1 contraction is Ca 2ϩ antagonist-insensitive and appears to involve activation and translocation of Ca 2ϩ -independent ⑀-PKC. Ca 2ϩ -independent contraction of ET-1 may account for limited efficacy of Ca 2ϩ channel blockers in some forms of cardiovascular dysfunction. Activation and translocation of Ca 2ϩ -independent ⑀-PKC may represent a signaling mechanism of 
